See more Optic Relief content here
Social distancing eye exams
See more Optic Relief content here
Adaptilens closes Series A financing round of $17.5 million to help drive development of the company's Accommodating Intraocular Lens
Claris Bio's journey toward treating neurotrophic keratitis
Study: Prevention of age-related truncation of γ-glutamylcysteine ligase catalytic subunit delays cataract formation
(EyePod) From idea to impact: Navigating ophthalmic innovation
Aurion Biotech completes dosing of all subjects in Phase 1/2 CLARA trial
Companies prepare to unveil research at ARVO 2024 conference
Adaptilens closes Series A financing round of $17.5 million to help drive development of the company's Accommodating Intraocular Lens
Claris Bio's journey toward treating neurotrophic keratitis
Study: Prevention of age-related truncation of γ-glutamylcysteine ligase catalytic subunit delays cataract formation
(EyePod) From idea to impact: Navigating ophthalmic innovation
Aurion Biotech completes dosing of all subjects in Phase 1/2 CLARA trial
Companies prepare to unveil research at ARVO 2024 conference